Long-term isoagglutinin monitoring after ABO-incompatible kidney transplantation
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae122 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Han Joo Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: ABO Blood-Group System, Blood Group Incompatibility, Graft Rejection, Hemagglutinins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Objectives
This study aimed to evaluate whether a 2-week period of daily isoagglutinin titer testing after ABO-incompatible kidney transplantation (ABOi-KT) is sufficient to ensure successful engraftment and to advocate for an extension of the monitoring duration in specific situations.
Methods
We reviewed patients from January 2022 to December 2023 at Asan Medical Center who underwent therapeutic plasma exchange (TPE) due to elevated ABO antibody titers and suspected acute antibody-mediated rejection (AMR) after ABOi-KT. Data collected included pre- and posttransplantation laboratory results, clinical and procedural information, imaging studies, and needle biopsy results of the renal graft.
Results
We encountered 3 cases of acute AMR 2 weeks after transplantation. All cases exhibited simultaneous increases in anti-ABO antibody isoagglutinin titers, creatinine, and C-reactive protein levels. Clinical signs, including fever, suggested possible infection, and renal graft biopsy, confirmed AMR in all cases. Two cases underwent graftectomy, while the third recovered renal function after conservative treatment, including TPE.
Conclusions
Our findings suggest that a 2-week monitoring period for isoagglutinin titers after ABOi-KT may not be sufficient to detect late AMR. Extending the monitoring duration and considering lifelong fresh-frozen plasma transfusion with graft-compatible blood types, along with periodic isoagglutinin titer testing in cases of suspected AMR, may improve long-term graft outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Laboratory Medicine, Kangdong Sacred Heart Hospital, Seoul, South Korea.
- Department of Laboratory Medicine, Seoul National University Hospital, Seoul, South Korea.
- Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
ORCID-Profile: Han Joo Kim, Yousun Chung, Dae-Hyun Ko
Zitieren
APA
Kim, H. J., Chung, Y., Kim, H., Ko, Y., Kim, Y. H., Hwang, S. H., Oh, H. B., & Ko, D. H. (2025). Long-term isoagglutinin monitoring after ABO-incompatible kidney transplantation. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae122
Vancouver
Kim HJ, Chung Y, Kim H, Ko Y, Kim YH, Hwang SH, et al. Long-term isoagglutinin monitoring after ABO-incompatible kidney transplantation. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae122
BibTeX
@article{Kim2025,
author = {Kim, Han Joo and Chung, Yousun and Kim, Hyungsuk and Ko, Youngmin and Kim, Young Hoon and Hwang, Sang-Hyun and Oh, Heung-Bum and Ko, Dae-Hyun},
title = {Long-term isoagglutinin monitoring after ABO-incompatible kidney transplantation},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae122}
}
EUVIMED